Table 1 Summary of characteristics of the randomized controlled trials (RCTs) included
Study(author) | year | Journal | Country | Process | Alginate Type & Key Composition | Number of patients | Male(n) | Female(n) | Mean age (sd) | Area treated | Outcomes |
|---|---|---|---|---|---|---|---|---|---|---|---|
For Donor-site wound (DSW) | |||||||||||
Attwood [15] | 1989 | Brirish Journal of Plasric Surgery | U.K | Calcium alginate | Calcium alginate (High G-content) | 105 | 77 | 28 | - | - | (1) |
Traditional dressing of paraffin gauze | 25 | 21 | 4 | - | - | ||||||
Porter [16] | 1991 | Brirish Journal of Plasric Surgery | U.K | Alginate | Biatain Alginate Ag (Calcium alginate, High M-content) | 29 | 14 | 15 | 51.9 (13–84) | - | (1)(4) |
Hydrocoilloid | 30 | 16 | 14 | 51.4 (18–84) | - | ||||||
Vanstraelen [17] | 1992 | Burns | U.K | Calcium sodium alginafe | Sodium alginate (M/G ratio not reported) | 20 | 9 | 11 | 61 | - | (1)(4) |
Porcine xenograft | - | - | - | ||||||||
Bettinger [18] | 1995 | Journal of Burn Care & Rehabilitation | U.S.A | Calcium alginate | Calcium alginate (High G-content) | 7 | - | - | 45 | 4 × 8 cm2 | (1)(3) |
Scarlet red | - | ||||||||||
Ho [19] | 2001 | Burns | China | standard skin donor site dressing Kaltostat (calcium sodium alginate) | Kaltostat (Calcium alginate, High M-content) | 35 | 30 | 5 | 31.7 ± 19.2 | 18.9 ± 16.3%TBSA | (1)(4) |
Hyphecan (1–4,2-acetamide-deoxy-B-D-glucan) | - | ||||||||||
Pannier [20] | 2002 | Annales De Chirurgie Plastique Esthetique | France | Calcium alginate | Sodium alginate (M/G ratio not reported) | 34 | - | - | 4.1 (1–15.5) | 102 (75–150) cm2 | (1)(4) |
Paraffin gauze | 33 | - | - | 4.9 (0.9–11.1) | 104 (69–125) cm2 | ||||||
Melandri [21] | 2006 | Burns | Italy, Switzerland | Algisite MTM | Sodium alginate (M/G ratio not reported) | 23 | 14 | 9 | 52.7 ± 17.0 | - | (4) |
Jaloskin1 | - | ||||||||||
Higgins [22] | 2012 | Int Wound J | Australia | calcium alginate, Kaltostat® | Kaltostat® (Calcium alginate, High M-content) | 18 | 10 | 8 | - | - | (2)(3)(4) |
polyurethane dressing, AllevynTM | 18 | 6 | 12 | - | - | ||||||
Ding [23] | 2013 | Burns | China | Alginate Silver (coloplast) | Alginate Silver (Calcium alginate, High M-content), Aquacel Ag (Sodium alginate (M/G ratio not reported)) | 10 | 7 | 3 | 39.0 ± 10.1 | - | (1)(4) |
Aquacel Ag (convatec) | 10 | 6 | 4 | 37.2 ± 11.0 | - | ||||||
Ding [24] | 2023 | Journal of Wound Care | China | Biatain Alginate Ag (Coloplast, Denmark) | Biatain Alginate Ag (Calcium alginate, High M-content), Biatain Ag (without calcium alginate) | 16 | 8 | 8 | 40 ± 12 | (1)(4) | |
Biatain Ag | - | ||||||||||
For Burn wound | |||||||||||
Opasanon [25] | 2010 | Int Wound J | Thailand | Askina Calgitrol Ag® (B. Braun Hospicare Ltd, Collooney Co. Sligo, Ireland), alginate silver wound dressing, | Sodium alginate (M/G ratio not reported) | 30 | 21 | 9 | 31.03 ± 19.76 | 7.93 ± 1.18%TBSA | (1)(2)(3) |
1% AgSD | 35 | 15 | 20 | 42.31 ± 23.49 | 2.77 ± 0.41%TBSA | ||||||
Carvalho [26] | 2011 | J Wound Ostomy Continence Nursing | Brazil | Collagen- alginate dressing covered with a transparent polyurethane film dressing | Calcium alginate (High G-content) | 12 | - | - | 36 ± 18 | TBSA% less than 15% | (1)(3)(4) |
Trans- parent polyurethane film dressings only | 11 | - | - | ||||||||
Brenner [27] | 2015 | Journal of Burn Care & Research | U.S.A | KaltostatAlginate dressing | Calcium alginate (High G-content) | 18 | 11 | 7 | - | 84 cm2 (42–399cm2) | (4) |
Allevyn dressing | 19 | 12 | 7 | - | 61cm2 (8–600cm2) | ||||||
Mehta [28] | 2019 | Journal of Family Medicine and Primary Care | India | Silver‐sulfadiazine‐impregnated collagen (SIC), a type 1 collagen impregnated with silver sulfadiazine (SSD)‐loaded alginate microspheres to deliver SSD | Sodium alginate (M/G ratio not reported) | 25 | 10 | 15 | 23.11 ± 20.67 | - | (1)(3)(4) |
Conventional dressings (with 1% SSD cream) | 25 | 11 | 14 | 22.95 ± 20.19 | - | ||||||
Rashaan [29] | 2019 | WOUND REPAIR AND REGENERATION | Netherlands | Flaminal® Forte | Sodium alginate (M/G ratio not reported) | 41 | 32 | 9 | 50.2 ± 15.4 | 3 (0.75–10) % TBSA | (1)(4) |
Flamazine® (silver sulfadiazine) | 48 | 39 | 9 | 42.6 ± 16.2 | 3 (0.5–16) % TBSA | ||||||